EPRX ▼ -4.4% - Eupraxia Pharmaceuticals Inc.
$EPRX - Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
15-OCT-2026 08:00 AM ET
Share this post
More filings for $EPRX
EPRX ▲ +2.0% - Eupraxia Pharmaceuticals Inc.Sep 30, 2026EPRX - Eupraxia Pharmaceuticals Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026
View full $EPRX filing history →💬 Comments
Loading comments…
Leave a comment